75 results about "Serotonin" patented technology

The present invention aims to provide a method for evaluating the serotonin reuptake inhibitory effect of a composition containing valerian extract. [Solution] The present invention provides a method for evaluating antidepressant effects, which involves quantitatively analyzing one or more components contained in at least a part of a plant of the genus Valerian or a processed product thereof, and evaluating the antidepressant effect of the test substance by referring to the results of the quantitative analysis and criteria for antidepressant effect.

The present invention provides a compound which has a serotonin 5-HT2A receptor inverse agonist effect, a pharmaceutically acceptable salt thereof, and a composition which is for serotonin 5-HT2A receptor inverse agonism and which contains the compound or the salt. Provided is a composition which is for serotonin 5-HT2A receptor inverse agonism and which contains a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (I) (In formula (I), R1 is a substituted or unsubstituted aromatic heterocyclic group or the like, each R2 is independently a hydrogen atom or the like, each R3 is independently a hydrogen atom or the like, n is 1 or 2, R4 is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group, L is -NR8- or the like, R8 is a hydrogen atom or the like, each R5 is independently a hydrogen atom or the like, each R6 is independently a hydrogen atom or the like, p is 1 or 2, and R7 is a group represented by the other formula shown.) (In the other formula shown, R9 is substituted or unsubstituted alkyloxy or the like, R10 is a hydrogen atom or the like, R11 is halogen or the like, and m is 0 or 1.)

Provided are a compound having serotonin 5-HT2A receptor antagonism and / or inverse agonism, a pharmaceutically acceptable salt thereof, and a composition for serotonin 5-HT2A receptor antagonism and / or inverse agonism comprising them.A compound represented by Formula (I):wherein R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is each independently a hydrogen atom or the like; R3 is each independently a hydrogen atom or the like; n is 1 or the like; a combination of (L1, L2) is (NH, N) or the like; R4 is a group represented by Formula:wherein p and q are each independently 2 or the like; Ra is substituted or unsubstituted alkyl or the like; Xb is each independently CRbRb′; Rb is each independently a hydrogen atom or the like; Rb′ is each independently a hydrogen atom or the like; Xc is each independently CRcRc′; Rc is each independently a hydrogen atom or the like; Rc′ is each independently a hydrogen atom or the like; Xd is CRd or the like; and Rd is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; and R7 is a group represented by Formula:wherein A is CR11 or the like; R9 is substituted or unsubstituted alkyloxy or the like; R10 is a hydrogen atom or the like; and R11 is each independently a hydrogen atom or the like; or a pharmaceutically acceptable salt thereof.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

The application discloses a method for differentiating stem cells into caudal serotonergic neurons, a complete culture medium and application. Specifically, a new culture medium is formed by adding small molecule compounds, so that human pluripotent stem cells are gradually induced to obtain hindbrain neural stem cells, ventral hindbrain caudal neural stem cells, serotonergic precursor cells and caudal serotonergic neurons of the hindbrain. The culture method is simple, and can efficiently obtain mature serotonergic neurons of specific regions, thereby providing an effective cell model for research on diseases related to the serotonergic system.

The purpose of the present disclosure is to provide a novel plant environmental stress alleviator, a plant growth promoter, and a plant DNA repair promoter that have an excellent effect of alleviating environmental stresses such as high temperatures.　The present disclosure provides a plant environmental stress alleviator, a plant growth promoter, and a plant DNA repair promoter containing: one or more neurotransmitters selected from choline esters, catecholamines, serotonin, and amino acids, and / or one or more acetylcholinesterase inhibitors selected from polyphenols, flavonoids, and organic acids, or a plant extract containing said inhibitors; and calcium ions. The present disclosure also provides a method for producing the aforementioned agents.

Provided herein are pharmaceutical compositions, kits comprising pharmaceutical compositions, methods of treating disease, and methods of making compositions. The pharmaceutical compositions described herein are powdery pharmaceutical compositions, which can contain encapsulated pharmaceutical agents, such as serotonin receptor agonists. The powdery pharmaceutical compositions may be administered by an inhaler device described herein.

The present disclosure relates to indole derivatives of general Formula (I), to processes for their preparation, to compositions including them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders, or conditions by activation of a serotonin receptors in a cell. The diseases, disorders, or conditions include, for example, psychosis, mental illnesses, and central nervous system (CNS) disorders.

To provide a new lactic acid bacterium and its use.SOLUTION: The features of the present invention for solving the above problems are as follows. It is characterized in that it can be used for various health-promoting applications using lactic acid bacteria Lacticaseibacillusparacaseisp. Shidare (accession number NITEABP-04138). Specifically, this lactic acid bacterium is characterized by exhibiting various effects such as promotion of production of IgA, IL-10, IL-12, and serotonin, normalization of stool shape and improvement of bowel movement, improvement of feeling of incomplete evacuation, adjustment of intestinal environment, immunoregulatory action, promotion of equol production, and further, promotion of collagen gene and hyaluronic acid gene expression, and EMT suppression.SELECTED DRAWING: None

The invention relates to a method for promoting tobacco leaves to quickly generate serotonin, and belongs to the field of biotechnology and plant metabolic engineering.The method includes the steps that serotonin in walnuts is identified to synthesize key genes, cDNA of the key genes is used as a template to amplify target fragments, a pHREAC expression vector is constructed and then introduced into agrobacterium tumefaciens, and the serotonin is obtained; and injecting the bacterial liquid into the lower epidermis of the tobacco leaf by using a syringe without a needle head for transient expression. And high-efficiency expression of exogenous genes can be realized within 3-5 days. The method does not need a complex procedure of gene operation breeding, does not require stable expression of transgenosis, is simple and convenient to operate, short in period and high in efficiency, and is suitable for rapid development of functional components and plant metabolism engineering application.

The technical scheme provided by the invention is application of quercetin in aquaculture, in particular to application of quercetin in preparation of drugs and / or feeds for preventing and treating thyroxine disorder and / or serotonin disorder of aquatic animals. The invention has the beneficial technical effects that the natural plant component quercetin which is originally applied to medicines and health care products for people is expanded to be applied to the field of aquatic animals, so that the nutrition required by the aquatic animals can be provided, the effect of regulating thyroid hormone and / or serotonin disorder of the aquatic animals can be achieved, the quercetin is used for replacing hormone medicines, and the health care effect is good. The method is friendly to an ecological chain, and green, cyclic and sustainable development is realized.

Provided are compounds having a serotonin 5-HT2A receptor inverse agonism, pharmaceutically acceptable salts thereof, and a composition comprising them,A composition comprising the compounds of Formula (I):or pharmaceutically acceptable salts thereof,wherein: R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is each independently a hydrogen atom or the like; R3 is each independently a hydrogen atom or the like; n is 1 or 2; R4 is substituted or unsubstituted non-aromatic nitrogen-containing heterocyclyl or the like; L is —NR8— or the like; R8 is a hydrogen atom or the like; R5 is each independently a hydrogen atom or the like; R6 is each independently a hydrogen atom or the like; p is 1 or 2; and R7 is a group represented by Formula:wherein R9 is substituted or unsubstituted alkyloxy or the like; R10 is a hydrogen atom or the like; R11 is halogen or the like; and m is 0 or 1.

This invention relates to the application of a traditional Chinese medicine composition in the preparation of a drug for neurogenic headache. The composition is characterized by being prepared from Rehmannia glutinosa (processed), Cornus officinalis, Dioscorea opposita, Alisma plantago-aquatica, Paeonia suffruticosa, and Poria cocos. The composition significantly reduces the number of head scratches in rats with nitroglycerin-induced neurogenic headache, decreases the levels of neurogenic headache-related factors (NO, CGRP) in plasma, improves reserpine-induced low serotonin (5-HT) symptoms in mice, and increases clotting time, suggesting that this traditional Chinese medicine composition has a good therapeutic effect on neurogenic headache.

The present invention relates to novel 5HT receptor modulators, such as compounds of the general Formula (I) and general Formula (II): or a pharmaceutically acceptable salt thereof. Methods of using the compounds include, for example, modulation of 5-hydroxytryptamine (5-HT) receptor subtypes, including 5-hydroxytryptamine 2A receptor and / or 5-hydroxytryptamine 2C receptor, and treatment of a condition or disease where the treatment is associated with the modulation of 5-hydroxytryptamine 2A receptor and / or 5-hydroxytryptamine 2C receptor.

Subject matter of the present invention is iron supplementation for treatment and / or prophylaxis of an affective disorder and / or post-traumatic stress disorder (PTSD) and / or serotonin-dependent diseases in a human patient in need thereof. Subject matter of the present invention is in particular iron supplementation for treatment and / or prophylaxis of depression, in particular of a major depressive disorder (MDD) in a human patient in need thereof.

Provided herein are compositions relating to psychedelics and serotonin receptor modulators. Further provided herein are methods of suppressing or halting hallucinogenic effects of a psychedelic and methods of treating a disease or disorder (e.g., depression or diseases or disorders related to depression) comprising administering psychedelics and serotonin receptor modulators.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

This disclosure relates to phenethylamine compounds, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, polymorphs, or prodrugs and pharmaceutical compositions thereof, and in some embodiments, to serotonin 5-HT2 receptor agonists and their use in the treatment of diseases related to the 5-HT2 receptor.

The invention belongs to the technical field of active component and target screening, and relates to a purple sweet potato leaf uric acid reducing active component and a potential target and a screening method thereof, the active component comprises rhododendron yellow, 3, 4, 2 ', 4', 6 '-pentahydroxychalcone, apigenin, quercetin glycoside, 6-hydroxycoumarin, 6, 6-dihydroxycoumarin, 3, 4, 2', 4 ', 6'-pentahydroxychalcone, 3, 4, 2 ', 4', 6 '-pentahydroxychalcone, 3, 4, 2', 4 '-pentahydroxychalcone, the component A is prepared from 2, 7-dihydroxy coumarin, daphnetin, trigonelline, serotonin, salidroside, sesamin and nicotinamide; the potential target spots comprise INS, PPAR-gamma, IL1-beta, PPAR-alpha, XDH and ABCG2; the method comprises the following steps: preparing purple sweet potato leaves and a sweet potato leaf water extract, determining the uric acid generation inhibition activity of the purple sweet potato leaves through an in-vitro experiment, and carrying out differential metabonomics combined network pharmacology analysis to excavate functional substances for reducing uric acid in the purple sweet potato leaves, thereby providing a material basis for high-valued utilization of the purple sweet potato leaves and development of functional foods for reducing uric acid.

The present disclosure generally relates to smart contact lenses for non-invasive monitoring of biological markers of health and disease. In some aspects, contact lenses comprising an electrochemical sensor between two deformable polymer lenses are provided. In some embodiments, the electrochemical sensor comprises a working electrode, a counter electrode, and a reference electrode. The working electrode, in some embodiments, further comprises an electrochemically reactive compound, that when oxidized, oxidizes a target analyte in a tear fluid. Other aspects of the disclosure relate to methods of using said contact lenses. For example, in some embodiments, the methods relate to determining a concentration of the target analyte in tear fluid. In some embodiments, the target analyte is serotonin. Other embodiments are generally directed to methods of making or using the contact lenses, kits involving said contact lenses, or the like.

A pharmaceutical composition includes a Pickering emulsion O / W containing an aqueous phase, a vegetal oil phase and an organically modified phyllosilicate, in particular for use to increase the production of TAFA4, and possibly to increase the production of serotonin, for use as an anti-inflammatory and / or anti-allergy agent.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

The composition for promoting serotonin production comprises one or more species selected from the group consisting of a bacterium that is Bifidobacterium bifidum MCC2085 (NITE BP-03881), a culture of the bacterium, and a treated product of the bacterium. The composition for promoting serotonin production comprises one or more selected from the group consisting of a bacterium that is Bifidobacterium longum subsp. Infantis M-63 (NITE BP-02623), a culture of the bacterium, and a treatment of the bacterium.

The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and / or an effect of preventing the recurrence of the same.

This method for assisting the diagnosis of mental stress comprises: a step for measuring the concentrations of a plurality of components contained in a biological sample collected from a subject; classifying the detected persons based on the personality features; and generating stress diagnosis assistance information for diagnosing the degree of mental stress of the subject on the basis of the determined concentrations of the components including betaine, creatine, GABA, creatinine, serotonin, kynurenic acid, 3-hydroxybutyric acid, and citric acid and the classification of the personality characteristics. According to the method, information serving as a support for accurately diagnosing the presence or absence or degree of mental stress of a subject can be provided.

Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of making and using the same.

The invention generally concerns a CNS-targeting non-systemic formulation for regulating dopamine and / or serotonin levels in the central nervous system (CNS).

The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.